Eiger BioPharmaceuticals Inc expected to post a loss of 64  cents a share - Earnings Preview

Eiger Biopharmaceuticals

04/05/2022 03:02

* Eiger BioPharmaceuticals Inc  EIGR.OQ   EIGR.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 5. 
    * The Palo Alto California-based  company is expected to
report  a
10.7% increase in revenue to $4.037 million from $3.65 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Eiger
BioPharmaceuticals
Inc is for a loss of 64 cents per share. For the same quarter
last year, the company reported a loss of 51 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $29​, above​ its last closing price
of $6.85. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.67       -0.64      -0.64     Met     0
 Sep. 30 2021  -0.56       -0.56      -0.65     Missed  -15.9
 Jun. 30 2021  -0.54       -0.55      -0.57     Missed  -4.2​
 Mar. 31 2021  0.05        -0.02      -0.51     Missed  -2,061
 ​​Dec.        0.14        0.25       -0.57     Missed  -325.4
 31 2020                                                
 Sep. 30 2020  -0.55       -0.59      -0.52     Beat    11.6​
 Jun. 30 2020  -0.70       -0.71      -0.60     Beat    15.9
 Mar. 31 2020  -0.74       -0.80      -0.62     Beat    22.8
 This summary was machine generated May 4 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated